 All subjects received an induction regimen administered at Baseline Week 0 and Week 2. The open-label OL induction dose was based on the subjects Baseline body weight. Subjects weighing 40 kg were to receive 160 mg at Week 0 and 80 mg adalimumab at Week 2. Subjects weighing 40 kg were to receive 80 mg at Week 0 and 40 mg adalimumab at Week 2. 